Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

European News

Expert recommendations from the Future of Anticoagulation Report are to be undertaken to improve Atrial Fibrillation management

Management strategies in the new ESC Atrial Fibrillation Guidelines align with those identified in the Report to address the urgent public health...

Daiichi Sankyo Partners With World Thrombosis Day

Promoting awareness of venous thromboembolism and atrial fibrillation, helping to reduce preventable deaths

Expert report highlights urgent action needed to lessen the future impact of Atrial Fibrillation in Europe

Report[1] recommendations aim to improve management of AF as numbers expected to double from 8.8 to 17.9 million adults aged over 55 years between...

Daiichi Sankyo Master Prize: Award for the Best Graduate in Pharmaceutical Sciences at the University of Munich

Claudia Hildebrandt received the Daiichi Sankyo Master Prize 2014: Award for the best graduate of Pharmaceutical Sciences at the...

Plant Expansion: Daiichi Sankyo Inaugurates New Building for Pharmaceutical Development in Pfaffenhofen, Bavaria

  • Substantial investment of 13 Mio. Euros. Opening ceremony for new annexe after 2-year building period
  • Focus on Pharmaceutical Development: 100...

Global Survey of Cardiologists Highlights Complexity of Managing Non-Valvular Atrial Fibrillation and Reinforces Need for Individualized Approach to Patient Care

•    Findings show risk of bleeding, along with overall efficacy1, consistently ranked among top considerations for cardiologists when choosing a...

ESC Congress 2014: Make Your Heart Feel Good!

Visit Us at Booth J500!

World Hypertension Day 2014

Daiichi Sankyo “Makes Your Heart Feel Good!” with a pan-European charity initiative

Daiichi Sankyo Submits SAVAYSATM (edoxaban) Tablets New Drug Application to the U.S. FDA for Once-Daily Use for Stroke Risk Reduction in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism

Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial...

Launch of LIXIANA® in Japan

Daiichi Sankyo Submits Supplemental New Drug Application in Japan for LIXIANA® (Edoxaban Tosilate Hydrate) for New Indications